Xilio Therapeutics, Inc. (XLO) stock
XLONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3075% below fair value
$8.07−0.17 (-2.00%)
Close on Nov 13, 2026Market cap $46.69MP/E –Yield –
Xilio Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Xilio Therapeutics's operating margin for the twelve months ending Sep 30, 2026 was -74.9%. For fiscal 2025 it was -95.9%, against -954.9% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -95.9% | +859.0 |
| FY2024 | Dec 31, 2024 | -954.9% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -117.7% | −107.6 |
| Q2 FY2026 | Jun 30, 2026 | -18.7% | +159.0 |
| Q1 FY2026 | Mar 31, 2026 | -111.6% | +361.2 |
| Q4 FY2025 | Dec 31, 2025 | -86.5% | +704.1 |
| Q3 FY2025 | Sep 30, 2025 | -10.1% | +642.2 |
| Q2 FY2025 | Jun 30, 2025 | -177.7% | +446.1 |
| Q1 FY2025 | Mar 31, 2025 | -472.7% | – |
| Q4 FY2024 | Dec 31, 2024 | -790.5% | – |
| Q3 FY2024 | Sep 30, 2024 | -652.3% | – |
| Q2 FY2024 | Jun 30, 2024 | -623.8% | – |
See a number that looks wrong?